# Bria-OTS

Source: https://onco.cc/drugs/bria-ots/  
OnCo record `bria-ots` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Bria-OTS is a set of ready-made cell-based immunotherapies from BriaCell Therapeutics, matched to the patient. It is in an early trial in breast cancer, and prostate cancer is the next planned use.

## Summary

Bria-OTS is a platform of personalised off-the-shelf cell-based immunotherapies from BriaCell Therapeutics, in a phase 1/2 study initially targeting breast cancer, according to the company, which plans to extend it to prostate cancer. NCI SBIR Phase II grant 5R44CA281555-03 funds BriaCell's work on an off-the-shelf tumour cell vaccine with HLA-matching alleles for advanced metastatic prostate cancer.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-04
- Tags: pipeline
- Modality: Off-the-shelf cell-based immunotherapy platform
- Mechanism: Described by BriaCell Therapeutics as a platform of personalised off-the-shelf cell-based immunotherapies; its NCI award describes an off-the-shelf tumour cell vaccine carrying HLA-matching alleles.

## Sources

- BriaCell Therapeutics: https://briacell.com/
- NIH RePORTER: award 5R44CA281555-03: https://reporter.nih.gov/project-details/11398997

## Connected records

- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Off-the-shelf cancer vaccines](https://onco.cc/technologies/shared-antigen-vaccine/)
- companies: [BriaCell Therapeutics](https://onco.cc/companies/briacell/)

---
JSON: https://onco.cc/api/v1/entities/bria-ots.json